Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics is a clinical-stage neuromuscular disease company that focuses on developing therapeutics for individuals with genetically-driven neuromuscular diseases. The company's FORCE platform is designed to overcome limitations in delivering treatment to muscle tissue and the central nervous system. Dyne has a strong pipeline, including its lead candidate Z-rostudirsen, which has the potential for US sales of $900M in 2036. Additionally, the company's low-risk, high-reward candidate has the potential for significant success in the treatment of Duchenne's muscular dystrophy (DMD). With a strong IP portfolio and a global confirmatory Phase 3 trial scheduled for 2Q26, Dyne Therapeutics is well-positioned for future growth and success in the rare disease market.

Bears say

Dyne Therapeutics is a clinical-stage neuromuscular disease company focused on developing targeted therapeutics for genetically driven neuromuscular diseases. Despite the potential in its unique FORCE platform, the company is still in the early stages of development and faces significant competition in the rapidly advancing field of gene therapy and oligonucleotide therapeutics. With a current focus on DMD and DM1, the success of Dyne's pipeline will depend heavily on the outcome of its clinical trials and its ability to secure regulatory approvals. Given these risks and uncertainties, the potential for negative outcomes is significant, impacting the company's financial performance and valuation.

Dyne Therapeutics (DYN) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 10 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.